392 related articles for article (PubMed ID: 29510588)
1. Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas.
Nakano K; Takahashi S
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29510588
[TBL] [Abstract][Full Text] [Related]
2. Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas.
Sethi TK; Keedy VL
Curr Treat Options Oncol; 2016 Feb; 17(2):11. PubMed ID: 26931561
[TBL] [Abstract][Full Text] [Related]
3. Overview of « druggable » alterations by histological subtypes of sarcomas and connective tissue intermediate malignancies.
Penel N; Lebellec L; Blay JY; Robin YM
Crit Rev Oncol Hematol; 2020 Jun; 150():102960. PubMed ID: 32320927
[TBL] [Abstract][Full Text] [Related]
4. The past, present, and future of cytotoxic chemotherapy and pathway-directed targeted agents for soft tissue sarcoma.
Ryan CW; Desai J
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714556
[TBL] [Abstract][Full Text] [Related]
5. Targeted Chemotherapy in Bone and Soft-Tissue Sarcoma.
Harwood JL; Alexander JH; Mayerson JL; Scharschmidt TJ
Orthop Clin North Am; 2015 Oct; 46(4):587-608. PubMed ID: 26410647
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapy in bone and soft tissue sarcoma in children and adolescents.
Thompson PA; Chintagumpala M
Curr Oncol Rep; 2012 Apr; 14(2):197-205. PubMed ID: 22302601
[TBL] [Abstract][Full Text] [Related]
7. Novel pathways and molecular targets for the treatment of sarcoma.
Frith AE; Hirbe AC; Van Tine BA
Curr Oncol Rep; 2013 Aug; 15(4):378-85. PubMed ID: 23661264
[TBL] [Abstract][Full Text] [Related]
8. Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas.
Vincenzi B; Badalamenti G; Napolitano A; Spalato Ceruso M; Pantano F; Grignani G; Russo A; Santini D; Aglietta M; Tonini G
Crit Rev Oncol Hematol; 2017 Oct; 118():1-6. PubMed ID: 28917265
[TBL] [Abstract][Full Text] [Related]
9. Olaratumab: A Novel Platelet-Derived Growth Factor Receptor α-Inhibitor for Advanced Soft Tissue Sarcoma.
Andrick BJ; Gandhi A
Ann Pharmacother; 2017 Dec; 51(12):1090-1098. PubMed ID: 28778132
[TBL] [Abstract][Full Text] [Related]
10. [Soft tissue sarcomas and gastrointestinal stromal tumors].
Reichardt P
Internist (Berl); 2016 Mar; 57(3):245-56. PubMed ID: 26907871
[TBL] [Abstract][Full Text] [Related]
11. Regorafenib for the Treatment of Sarcoma.
Blay JY; Duffaud F; George S; Maki RG; Penel N
Curr Treat Options Oncol; 2022 Nov; 23(11):1477-1502. PubMed ID: 36178573
[TBL] [Abstract][Full Text] [Related]
12. Olaratumab in soft tissue sarcoma - Current status and future perspectives.
Antoniou G; Lee ATJ; Huang PH; Jones RL
Eur J Cancer; 2018 Mar; 92():33-39. PubMed ID: 29413687
[TBL] [Abstract][Full Text] [Related]
13. Management of elderly patients with bone and soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group.
Tanaka K; Ozaki T
Jpn J Clin Oncol; 2022 May; 52(6):526-530. PubMed ID: 35292817
[TBL] [Abstract][Full Text] [Related]
14. Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue Sarcomas Using DNA/RNA-based Clinical Sequencing.
Hasegawa N; Hayashi T; Niizuma H; Kikuta K; Imanishi J; Endo M; Ikeuchi H; Sasa K; Sano K; Hirabayashi K; Takagi T; Ishijima M; Kato S; Kohsaka S; Saito T; Suehara Y
Clin Orthop Relat Res; 2024 Mar; 482(3):549-563. PubMed ID: 38014853
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Targets for Bone and Soft-Tissue Sarcomas.
Miwa S; Yamamoto N; Hayashi K; Takeuchi A; Igarashi K; Tsuchiya H
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30621224
[TBL] [Abstract][Full Text] [Related]
16. Olaratumab for the treatment of soft-tissue sarcoma.
Pender A; Jones RL
Future Oncol; 2017 Oct; 13(24):2151-2157. PubMed ID: 28745071
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapies in soft tissue sarcomas.
Judson I
Ann Oncol; 2010 Oct; 21 Suppl 7():vii277-80. PubMed ID: 20943628
[TBL] [Abstract][Full Text] [Related]
18. Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial.
Toulmonde M; Penel N; Adam J; Chevreau C; Blay JY; Le Cesne A; Bompas E; Piperno-Neumann S; Cousin S; Grellety T; Ryckewaert T; Bessede A; Ghiringhelli F; Pulido M; Italiano A
JAMA Oncol; 2018 Jan; 4(1):93-97. PubMed ID: 28662235
[TBL] [Abstract][Full Text] [Related]
19. Targeting sarcomas: novel biological agents and future perspectives.
Mahalingam D; Mita A; Sankhala K; Swords R; Kelly K; Giles F; Mita MM
Curr Drug Targets; 2009 Oct; 10(10):937-49. PubMed ID: 19860642
[TBL] [Abstract][Full Text] [Related]
20. Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α.
Lowery CD; Blosser W; Dowless M; Knoche S; Stephens J; Li H; Surguladze D; Loizos N; Luffer-Atlas D; Oakley GJ; Guo Q; Iyer S; Rubin BP; Stancato L
Clin Cancer Res; 2018 Feb; 24(4):847-857. PubMed ID: 29191969
[No Abstract] [Full Text] [Related]
[Next] [New Search]
